Moderna Inc has projected higher vaccine sales for the second half of the year as it sees Covid-19 becoming a flu-like endemic illness, prompting people to take regular shots.
The company expects $19 billion in sales of its vaccine this year from $18.5 billion previously, and said talks were ongoing for vaccine orders in 2023.
Moderna has said its vaccine will be priced below value during the pandemic period, and that it will change its pricing strategy as Covid-19 shows signs of subsiding, Reuters reports.
